Radiotherapy for Melanoma: More than DNA Damage

Despite its reputation as a radioresistant tumour, there is evidence to support a role for radiotherapy in patients with melanoma and we summarise current clinical practice. Melanoma is a highly immunogenic tumour and in this era of immunotherapy, there is renewed interest in the potential of irradi...

Full description

Saved in:
Bibliographic Details
Main Authors: Susanne J. Rogers, Emsad Puric, Brigitte Eberle, Niloy R. Datta, Stephan B. Bodis
Format: Article
Language:English
Published: Wiley 2019-01-01
Series:Dermatology Research and Practice
Online Access:http://dx.doi.org/10.1155/2019/9435389
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832561226228432896
author Susanne J. Rogers
Emsad Puric
Brigitte Eberle
Niloy R. Datta
Stephan B. Bodis
author_facet Susanne J. Rogers
Emsad Puric
Brigitte Eberle
Niloy R. Datta
Stephan B. Bodis
author_sort Susanne J. Rogers
collection DOAJ
description Despite its reputation as a radioresistant tumour, there is evidence to support a role for radiotherapy in patients with melanoma and we summarise current clinical practice. Melanoma is a highly immunogenic tumour and in this era of immunotherapy, there is renewed interest in the potential of irradiation, not only as an adjuvant and palliative treatment, but also as an immune stimulant. It has long been known that radiation causes not only DNA strand breaks, apoptosis, and necrosis, but also immunogenic modulation and cell death through the induction of dendritic cells, cell adhesion molecules, death receptors, and tumour-associated antigens, effectively transforming the tumour into an individualised vaccine. This immune response can be enhanced by the application of clinical hyperthermia as evidenced by randomised trial data in patients with melanoma. The large fraction sizes used in cranial radiosurgery and stereotactic body radiotherapy are more immunogenic than conventional fractionation, which provides additional radiobiological justification for these techniques in this disease entity. Given the immune priming effect of radiotherapy, there is a strong but complex biological rationale and an increasing body of evidence for synergy in combination with immune checkpoint inhibitors, which are now first-line therapy in patients with recurrent or metastatic melanoma. There is great potential to increase local control and abscopal effects by combining radiotherapy with both immunotherapy and hyperthermia, and a combination of all three modalities is suggested as the next important trial in this refractory disease.
format Article
id doaj-art-7b2b1e5338514853a75186828d07076b
institution Kabale University
issn 1687-6105
1687-6113
language English
publishDate 2019-01-01
publisher Wiley
record_format Article
series Dermatology Research and Practice
spelling doaj-art-7b2b1e5338514853a75186828d07076b2025-02-03T01:25:35ZengWileyDermatology Research and Practice1687-61051687-61132019-01-01201910.1155/2019/94353899435389Radiotherapy for Melanoma: More than DNA DamageSusanne J. Rogers0Emsad Puric1Brigitte Eberle2Niloy R. Datta3Stephan B. Bodis4Centre for Radiation Oncology KSA-KSB, Kantonsspital Aarau, Aarau 5001, SwitzerlandCentre for Radiation Oncology KSA-KSB, Kantonsspital Aarau, Aarau 5001, SwitzerlandCentre for Radiation Oncology KSA-KSB, Kantonsspital Aarau, Aarau 5001, SwitzerlandCentre for Radiation Oncology KSA-KSB, Kantonsspital Aarau, Aarau 5001, SwitzerlandCentre for Radiation Oncology KSA-KSB, Kantonsspital Aarau, Aarau 5001, SwitzerlandDespite its reputation as a radioresistant tumour, there is evidence to support a role for radiotherapy in patients with melanoma and we summarise current clinical practice. Melanoma is a highly immunogenic tumour and in this era of immunotherapy, there is renewed interest in the potential of irradiation, not only as an adjuvant and palliative treatment, but also as an immune stimulant. It has long been known that radiation causes not only DNA strand breaks, apoptosis, and necrosis, but also immunogenic modulation and cell death through the induction of dendritic cells, cell adhesion molecules, death receptors, and tumour-associated antigens, effectively transforming the tumour into an individualised vaccine. This immune response can be enhanced by the application of clinical hyperthermia as evidenced by randomised trial data in patients with melanoma. The large fraction sizes used in cranial radiosurgery and stereotactic body radiotherapy are more immunogenic than conventional fractionation, which provides additional radiobiological justification for these techniques in this disease entity. Given the immune priming effect of radiotherapy, there is a strong but complex biological rationale and an increasing body of evidence for synergy in combination with immune checkpoint inhibitors, which are now first-line therapy in patients with recurrent or metastatic melanoma. There is great potential to increase local control and abscopal effects by combining radiotherapy with both immunotherapy and hyperthermia, and a combination of all three modalities is suggested as the next important trial in this refractory disease.http://dx.doi.org/10.1155/2019/9435389
spellingShingle Susanne J. Rogers
Emsad Puric
Brigitte Eberle
Niloy R. Datta
Stephan B. Bodis
Radiotherapy for Melanoma: More than DNA Damage
Dermatology Research and Practice
title Radiotherapy for Melanoma: More than DNA Damage
title_full Radiotherapy for Melanoma: More than DNA Damage
title_fullStr Radiotherapy for Melanoma: More than DNA Damage
title_full_unstemmed Radiotherapy for Melanoma: More than DNA Damage
title_short Radiotherapy for Melanoma: More than DNA Damage
title_sort radiotherapy for melanoma more than dna damage
url http://dx.doi.org/10.1155/2019/9435389
work_keys_str_mv AT susannejrogers radiotherapyformelanomamorethandnadamage
AT emsadpuric radiotherapyformelanomamorethandnadamage
AT brigitteeberle radiotherapyformelanomamorethandnadamage
AT niloyrdatta radiotherapyformelanomamorethandnadamage
AT stephanbbodis radiotherapyformelanomamorethandnadamage